A database of FDA approved therapeutic peptides and proteins
ID1001 | ThPPIDTh1001 | NameLepirudin | Peptide SequenceLVYTDCTESGQNLCLCEGSN Full view | Length65 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandRefludan | CompanyBerlex Labs | Physical AppearanceSterile, white, freeze-dried powder | Route of AdministartionIntravenous infusion | CategoryAntithrombins and Fibrinolytic Agents | TargetProthrombin |
ID1022 | ThPPIDTh1003 | NameDornase alfa | Peptide SequenceLKIAAFNIQTFGETKMSNAT Full view | Length255 | Functional ClassificationIb | DiseaseMetabolic | BrandPulmozyme | CompanyGenentech Inc | Physical AppearanceN.A. | Route of AdministartionAdministered by inhalation of an aerosol mist produced by a compressed air driven nebulizer system | CategoryEnzymes | TargetDNA |
ID1023 | ThPPIDTh1003 | NameDornase alfa | Peptide SequenceLKIAAFNIQTFGETKMSNAT Full view | Length255 | Functional ClassificationIb | DiseaseMetabolic | BrandViscozyme | CompanyRoche (Chile) | Physical AppearanceN.A. | Route of AdministartionAdministered by inhalation of an aerosol mist produced by a compressed air driven nebulizer system | CategoryEnzymes | TargetDNA |
ID1032 | ThPPIDTh1006 | NameBivalirudin | Peptide SequenceFPRPGGGGNGDFEEIPEEYL Full view | Length20 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAngiomax | CompanyMedicines Co or MDCO | Physical AppearanceWhite lyophilized cake in single-use vials | Route of AdministartionIntravenous infusion | CategoryAntithrombins | TargetProthrombin |
ID1033 | ThPPIDTh1006 | NameBivalirudin | Peptide SequenceFPRPGGGGNGDFEEIPEEYL Full view | Length20 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAngiox | CompanyThe Medicines Company UK Ltd | Physical AppearancePowder for concentrate for solution | Route of AdministartionInjection | CategoryAntithrombins | TargetProthrombin |
ID1055 | ThPPIDTh1009 | NameAlteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandActivase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous | CategoryThrombolytic Agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1067 | ThPPIDTh1012 | NameReteplase | Peptide SequenceSYQGNSDCYFGNGSAYRGTH Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandRetavase | CompanyCentocor | Physical AppearanceSterile, white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryFibrinolytic Agents, Thrombolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1148 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAdvate | CompanyN.A. | Physical AppearancePowder form | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1149 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAlphanate | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1150 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandBioclate | CompanyBaxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc. | Physical AppearanceSterile, nonpyrogenic, off-white to faint yellow, lyophilized powder | Route of AdministartionIntravenous infusion | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1151 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHelixate FS | CompanyN.A. | Physical AppearanceSterile, stable, purified, nonpyrogenic, dried concentrate | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1152 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHemofil M | CompanyN.A. | Physical AppearanceDry concentrate | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1153 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHyate:C | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1154 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandKoate-HP | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1155 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandKogenate FS | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1156 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandMonarc-M | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1157 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandMonoclate-P | CompanyN.A. | Physical AppearanceLyophilized powder for solution | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1158 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandReFacto | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1159 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandXyntha | CompanyN.A. | Physical AppearanceSterile, nonpyrogenic, preservative-free, freeze-dried powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1201 | ThPPIDTh1026 | NameAnistreplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIc | DiseaseHematological,Metabolic | BrandEminase | CompanyWulfing Pharma GmbH | Physical AppearanceDry powder | Route of AdministartionIntravenous infusion | CategoryThrombolytic Agents, Fibrinolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1210 | ThPPIDTh1028 | NameTenecteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandTNKase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryThrombolytic Agents, Fibrinolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1,Plasminogen activator inhibitor 2,Tetranectin,Keratin, type II cytoskeletal 8,Annexin A2,Calreticulin,Calnexin,Prolow-density lipoprotein |
ID1234 | ThPPIDTh1032 | NameCoagulation factor VIIa | Peptide SequenceANAFLEELRPGSLERECKEE Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandNovoSeven | CompanyNovo Nordisk | Physical AppearanceSterile, white lyophilized powder | Route of AdministartionInjection | CategoryThrombotic Agents, Coagulants | TargetCoagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor |
ID1252 | ThPPIDTh1035 | NameGlucagon recombinant | Peptide SequenceHSQGTFTSDYSKYLDSRRAQ Full view | Length29 | Functional ClassificationIV | DiseaseHormonal/Metabolic/genetic | BrandGlucaGen | CompanyNovo Nordisk | Physical AppearanceSterile, lyophilized white powder | Route of AdministartionSubcutaneous, Intramuscular, or Intravenous infusion | CategoryHypoglycemic Agents | TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
ID1253 | ThPPIDTh1035 | NameGlucagon recombinant | Peptide SequenceHSQGTFTSDYSKYLDSRRAQ Full view | Length29 | Functional ClassificationIV | DiseaseHormonal/Metabolic/genetic | BrandGlucagon | CompanyEli Lilly | Physical AppearancePowder | Route of AdministartionSubcutaneously or Intramuscularly Injection | CategoryHypoglycemic Agents | TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
ID1275 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog | CompanyEli Lilly | Physical AppearanceSterile, aqueous, clear, and colorless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1276 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog KwikPen | CompanyEli Lilly | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1277 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog Pen | CompanyEli Lilly | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1283 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus | CompanySanofi-Aventis | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1284 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus OptiSet | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1285 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus SoloStar | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1305 | ThPPIDTh1043 | NameRasburicase | Peptide SequenceSAVKAARYGKDNVRVYKVHK Full view | Length255 | Functional ClassificationIc | DiseaseMetabolic/Genetic | BrandElitek | CompanySanofi-Synthelabo Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous administration | CategoryAntihyperuricemic Agents, Gout suppressants | TargetUric acid |
ID1306 | ThPPIDTh1043 | NameRasburicase | Peptide SequenceSAVKAARYGKDNVRVYKVHK Full view | Length255 | Functional ClassificationIc | DiseaseMetabolic/Genetic | BrandFasturtec | CompanyN.A. | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionIntravenous administartion | CategoryAntihyperuricemic Agents, Gout suppressants | TargetUric acid |
ID1324 | ThPPIDTh1045 | NameImiglucerase | Peptide SequenceARPCIPKSFGYSSVVCVCNA Full view | Length255 | Functional ClassificationIa | DiseaseMetabolic | BrandCerezyme | CompanyGenzyme | Physical AppearanceSterile, non-pyrogenic, white to off-white lyophilized product | Route of AdministartionIntravenous infusion | CategoryEnzyme Replacement Agents | TargetGlucocerebroside |
ID1327 | ThPPIDTh1046 | NameAbciximab | Peptide SequenceH ReoPro-like antibo Full view | Length218 | Functional ClassificationIIa | DiseaseGenetic/Metabolic/Haemetological | BrandReoPro | CompanyEli Lilly and Company | Physical AppearanceClear, colorless, sterile, non-pyrogenic solution | Route of AdministartionIntravenous administartion | CategoryPlatelet Aggregation Inhibitors, Anticoagulants | TargetIntegrin beta-3,Integrin alpha-IIb,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immuno |
ID1331 | ThPPIDTh1047 | NameAlpha-1-proteinase inhibitor | Peptide SequenceEDPQGDAAQKTDTSHHDQDH Full view | Length255 | Functional ClassificationIIa | DiseaseMetabolic/Geneti/Respiratory | BrandAralast | CompanyBaxter | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous infusion | CategorySerine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | TargetNeutrophil elastase |
ID1332 | ThPPIDTh1047 | NameAlpha-1-proteinase inhibitor | Peptide SequenceEDPQGDAAQKTDTSHHDQDH Full view | Length255 | Functional ClassificationIIa | DiseaseMetabolic/Geneti/Respiratory | BrandProlastin | CompanyTalecris Biotherapeutics C formerly Bayer | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous infusion | CategorySerine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | TargetNeutrophil elastase |
ID1358 | ThPPIDTh1050 | NamePegademase bovine | Peptide SequenceMAQTPAFNKPKVELHVHLDG Full view | Length255 | Functional ClassificationIa | DiseaseMetabolic | BrandAdagen | CompanyEnzon Inc. | Physical AppearanceIsotonic, pyrogen free, sterile solution, pH 7.2-7.4 | Route of AdministartionIntramusular Injection | CategoryEnzyme Replacement Agents | TargetAdenosine,Growth factor receptor-bound protein 2 |
ID1361 | ThPPIDTh1051 | NameHuman Serum Albumin | Peptide SequenceMKWVTFISLLFLFSSAYSRG Full view | Length609 | Functional ClassificationIa | DiseaseHematological/Metabolic/genetic | BrandAlbuminar | CompanyCSL Behring | Physical AppearanceSterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. | Route of AdministartionAlbumin (Human) 25%, Albuminar-25 (albumin human) , is to be administered by the Intravenous route. | CategorySerum substitutes | TargetN.A. |
ID1362 | ThPPIDTh1051 | NameHuman Serum Albumin | Peptide SequenceMKWVTFISLLFLFSSAYSRG Full view | Length609 | Functional ClassificationIa | DiseaseHematological/Metabolic/genetic | BrandAlbutein | CompanyGRIFOLS | Physical AppearanceSterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). | Route of AdministartionAlbutein 20% is to be administered by the Intravenous route. | CategorySerum substitutes | TargetN.A. |
ID1363 | ThPPIDTh1052 | NameEptifibatide | Peptide SequenceMpr-Har-Gly-Asp-Trp- Full view | Length7 | Functional ClassificationIb | DiseaseHematological/Metabolic | BrandINTEGRILIN | CompanySchering-Plough/Essex | Physical AppearanceClear, colorless, sterile, non-pyrogenic solution of Eptifibatide | Route of AdministartionInjection Solution for IIntravenousUse | CategoryPlatelet Aggregation Inhibitors | TargetLutropin-choriogonadotropic hormone receptor,Follicle-stimulating hormone receptor |
ID1382 | ThPPIDTh1060 | NameInsulin, porcine | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic | Brandvetsulin | CompanyIntervet Inc (Merck Animal Health) | Physical AppearanceSterile injectable suspension in multidose vials containing 10 mL of 40 IU/mL porcine insulin zinc suspension | Route of AdministartionSubcutaneous Injection | CategoryHypoglycemic Agents | TargetInterferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Hyaluronan, Transforming growth factor beta-1 |
ID1422 | ThPPIDTh1071 | NamePancrelipase | Peptide SequencePancreatic alpha amy Full view | Length1206 | Functional ClassificationIa | DiseaseMetabolic/genetic/ | BrandPancrecarb | CompanyDigestive care US, Inc. | Physical AppearanceDelayed-Release Capsules, Buffered and Enteric-Coated Microspheres. | Route of AdministartionOral route | CategoryGastrointestinal Agents and Enzyme Replacement Agents | TargetSynaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
ID1423 | ThPPIDTh1071 | NamePancrelipase | Peptide SequencePancreatic alpha amy Full view | Length1206 | Functional ClassificationIa | DiseaseMetabolic/genetic/ | BrandViokace | CompanyAptalis Pharma US, Inc. | Physical AppearanceBeige-white amorphous powder, miscible in water and practically insoluble in alcohol and converted to tablet form | Route of AdministartionOral route | CategoryGastrointestinal Agents and Enzyme Replacement Agents | TargetSynaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
ID1424 | ThPPIDTh1071 | NamePancrelipase | Peptide SequencePancreatic alpha amy Full view | Length1206 | Functional ClassificationIa | DiseaseMetabolic/genetic/ | BrandULTRESA | CompanyAptalis Pharma US, Inc. | Physical AppearanceBeige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether and converted to Delayed-Release Capsules | Route of AdministartionOral route | CategoryGastrointestinal Agents and Enzyme Replacement Agents | TargetSynaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
ID1425 | ThPPIDTh1071 | NamePancrelipase | Peptide SequencePancreatic alpha amy Full view | Length1206 | Functional ClassificationIa | DiseaseMetabolic/genetic/ | BrandPERTZYE | CompanyDigestive care US, Inc. | Physical AppearanceBeige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether PERTZYE delayed-release capsule | Route of AdministartionOral route | CategoryGastrointestinal Agents and Enzyme Replacement Agents | TargetSynaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
ID1426 | ThPPIDTh1071 | NamePancrelipase | Peptide SequencePancreatic alpha amy Full view | Length1206 | Functional ClassificationIa | DiseaseMetabolic/genetic/ | BrandULTRASE | CompanyAxcan Pharma | Physical AppearanceCapsules Enteric-Coated Microspheres | Route of AdministartionOral route | CategoryGastrointestinal Agents and Enzyme Replacement Agents | TargetSynaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
ID1427 | ThPPIDTh1071 | NamePancrelipase | Peptide SequencePancreatic alpha amy Full view | Length1206 | Functional ClassificationIa | DiseaseMetabolic/genetic/ | BrandZENPEP | CompanyAptalis Pharma US, Inc. | Physical AppearanceDelayed-Release Capsules | Route of AdministartionOral route | CategoryGastrointestinal Agents and Enzyme Replacement Agents | TargetSynaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
ID1428 | ThPPIDTh1072 | NameStreptokinase | Peptide SequenceMKNYLSFGMFALLFALTFGT Full view | Length440 | Functional ClassificationIc | DiseaseMetabolic/Haemetological | BrandStreptase | CompanyCSL Behring | Physical AppearanceSterile, purified preparation formulated as lypholized powder | Route of AdministartionIntravenous and intracoronary administration. | CategoryFibrinolytic Agents and Thrombolytic Agents | TargetN.A. |
ID1434 | ThPPIDTh1074 | NameAlglucerase | Peptide SequenceARPCIPKSFGYSSVVCVCNA Full view | Length497 | Functional ClassificationIa | DiseaseMetabolic | BrandCeredase | CompanyGenzyme Corporation | Physical AppearanceClear sterile non-pyrogenic solution of alglucerase in a citrate buffered solution | Route of AdministartionIntravenous injection | CategoryEnzyme Replacement Agents | TargetPlasminogen,Proteinase-activated receptor 1 |
ID1437 | ThPPIDTh1076 | NameLaronidase | Peptide SequenceAPHLVQVDAARALWPLRRFW Full view | Length626 | Functional ClassificationIa | DiseaseMetabolic | BrandALDURAZYME | CompanyGenzyme Corporation | Physical AppearanceSterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection | Route of AdministartionIntravenous infusion | CategoryEnzyme Replacement Agents | TargetN.A. |